Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Sells $1,064,700.00 in Stock

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) insider Robert Berman sold 35,000 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $30.42, for a total value of $1,064,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Robert Berman also recently made the following trade(s):

  • On Wednesday, January 10th, Robert Berman sold 35,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $27.52, for a total value of $963,200.00.
  • On Tuesday, December 19th, Robert Berman sold 10,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $24.10, for a total value of $241,000.00.
  • On Monday, December 11th, Robert Berman sold 25,000 shares of Biohaven Pharmaceutical stock. The stock was sold at an average price of $21.28, for a total value of $532,000.00.

Shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE BHVN) traded down $1.27 during trading hours on Wednesday, hitting $29.90. The stock had a trading volume of 225,088 shares, compared to its average volume of 431,413. Biohaven Pharmaceutical Holding Co Ltd has a 1 year low of $17.00 and a 1 year high of $39.51. The company has a market capitalization of $1,100.00 and a P/E ratio of -5.73.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Tuesday, November 14th. The company reported ($1.19) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.03. sell-side analysts anticipate that Biohaven Pharmaceutical Holding Co Ltd will post -6.4 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of the company. VHCP Management II LLC increased its holdings in shares of Biohaven Pharmaceutical by 3.3% during the fourth quarter. VHCP Management II LLC now owns 1,718,605 shares of the company’s stock valued at $46,368,000 after acquiring an additional 54,305 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Biohaven Pharmaceutical by 84.9% during the fourth quarter. Alliancebernstein L.P. now owns 1,597,756 shares of the company’s stock valued at $43,107,000 after acquiring an additional 733,526 shares in the last quarter. BlackRock Inc. increased its holdings in shares of Biohaven Pharmaceutical by 1.1% during the fourth quarter. BlackRock Inc. now owns 1,154,207 shares of the company’s stock valued at $31,139,000 after acquiring an additional 12,505 shares in the last quarter. Eagle Asset Management Inc. increased its holdings in shares of Biohaven Pharmaceutical by 20.4% during the fourth quarter. Eagle Asset Management Inc. now owns 1,104,999 shares of the company’s stock valued at $30,207,000 after acquiring an additional 187,243 shares in the last quarter. Finally, Carillon Tower Advisers Inc. bought a new position in shares of Biohaven Pharmaceutical during the fourth quarter valued at $18,627,000. Hedge funds and other institutional investors own 48.09% of the company’s stock.

A number of equities analysts have issued reports on BHVN shares. Canaccord Genuity started coverage on Biohaven Pharmaceutical in a report on Friday, December 15th. They issued a “buy” rating and a $30.00 price objective for the company. Piper Jaffray Companies set a $48.00 price objective on Biohaven Pharmaceutical and gave the stock a “buy” rating in a report on Monday, December 11th. Zacks Investment Research upgraded Biohaven Pharmaceutical from a “hold” rating to a “buy” rating and set a $25.00 price objective for the company in a report on Monday, December 4th. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price objective on shares of Biohaven Pharmaceutical in a report on Wednesday, November 15th. Finally, BidaskClub downgraded Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a report on Friday, October 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Biohaven Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $36.14.

WARNING: “Biohaven Pharmaceutical Holding Co Ltd (BHVN) Insider Sells $1,064,700.00 in Stock” was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of US & international trademark & copyright laws. The legal version of this story can be read at https://www.americanbankingnews.com/2018/02/14/biohaven-pharmaceutical-holding-co-ltd-bhvn-insider-sells-1064700-00-in-stock.html.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Insider Buying and Selling by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply